Consultancy.uk featured Stratence Partners following EPA Amsterdam 2026, highlighting how healthcare organizations can transform pricing pressure, fragmented data, and Gross-to-Net complexity into structured, AI-Powered commercial decision systems.

Gross-to-Net is no longer a reporting exercise. Discover how leading organizations turn pricing complexity into sustainable revenue through structured governance and AI-powered commercial systems.

At EPA Amsterdam 2026, Fernando Ventureira, CEO of Stratence Partners, presented two sessions addressing critical challenges for pharmaceutical and MedTech companies: mastering Gross to Net complexity and embedding AI into commercial decision making. This article summarizes the key insights on how organizations can transform pricing, access, and commercial execution into a unified performance system.

In Medical Devices, margin erosion rarely comes from innovation. It comes from fragmented commercial governance. Stratence Partners explains how Commercial Transformation, AI Powered, restores structural control and delivers measurable EBIT impact within year one.